menu
    • menu

    Company profile for Foghorn Therapeutics

    NEW Drugs in Dev: 3
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic ControlTM Product Platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us – and rewrite destiny for millions...
    Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic ControlTM Product Platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us – and rewrite destiny for millions of people living with disease. With the Gene Traffic ControlTM Product Platform, Foghorn® Therapeutics is discovering and developing an unprecedented class of medicines targeting diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Foghorn TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    100 Binney Street, Suite 610, Cambridge, MA 02142
    Telephone
    Telephone
    617-586-3100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://foghorntx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/foghorn-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Foghorn Therapeutics Shares 2025-26 Financial and Strategic Plans
    Foghorn Therapeutics Shares 2025-26 Financial and Strategic Plans

    11 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/11/3254140/0/en/Foghorn-Therapeutics-Provides-Financial-Update-for-2025-and-2026-Strategic-Outlook.html

    GLOBENEWSWIRE
    11 Mar 2026
    Share Share
    Foghorn Therapeutics To Join Two Investor Conferences
    Foghorn Therapeutics To Join Two Investor Conferences

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3243365/0/en/Foghorn-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Foghorn Therapeutics Appoints Ryan Maynard As CFO
    Foghorn Therapeutics Appoints Ryan Maynard As CFO

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242457/0/en/Foghorn-Therapeutics-Strengthens-Financial-Leadership-with-Appointment-of-Ryan-Maynard-as-Chief-Financial-Officer.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Yatiri Bio Predicts AML Drug Response With Foghorn's FHD-286
    Yatiri Bio Predicts AML Drug Response With Foghorn's FHD-286

    10 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/10/3235109/0/en/Yatiri-Bio-Accurately-Predicts-AML-Drug-Response-in-Blinded-Study-Using-Foghorn-s-FHD-286.html

    GLOBENEWSWIRE
    10 Feb 2026
    Share Share
    Foghorn Therapeutics to Participate in the Guggenheim Summit
    Foghorn Therapeutics to Participate in the Guggenheim Summit

    03 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/03/3230909/0/en/Foghorn-Therapeutics-to-Participate-in-the-Guggenheim-Emerging-Outlook-Biotech-Summit.html

    GLOBENEWSWIRE
    03 Feb 2026
    Share Share
    Foghorn Therapeutics Closes $50M Financing At 30% Premium
    Foghorn Therapeutics Closes $50M Financing At 30% Premium

    13 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/13/3218246/0/en/Foghorn-Therapeutics-Announces-Closing-of-50-Million-Registered-Direct-Financing-at-a-30-Premium.html

    GLOBENEWSWIRE
    13 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search